Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2016', provides in depth analysis on Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted pipeline therapeutics. 

The report provides comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) 
- The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Overview 6
Therapeutics Development 7
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Stage of Development 7
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Therapy Area 8
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Indication 9
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Companies 12
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Universities/Institutes 14
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development 22
Agilvax Inc 22
Bavarian Nordic A/S 23
Emergent BioSolutions Inc 24
F. Hoffmann-La Roche Ltd 25
Trellis Bioscience Inc 26
Visterra Inc 27
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles 28
AX-14 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
MVA-RSV - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
respiratory syncytial virus vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
respiratory syncytial virus vaccine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
TRL-3D3 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
VIS-RSV - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Projects 37
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Featured News & Press Releases 38
Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine 38
Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine 38
Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium 39
Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine 39
May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations 39
Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus 40

Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Agilvax Inc, H2 2016 22
Pipeline by Bavarian Nordic A/S, H2 2016 23
Pipeline by Emergent BioSolutions Inc, H2 2016 24
Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 25
Pipeline by Trellis Bioscience Inc, H2 2016 26
Pipeline by Visterra Inc, H2 2016 27
Dormant Projects, H2 2016 37